Praxis Precision Medicines Q3 Net Loss Widens, Collaboration Revenue Falls; Shares Drop Pre-Bell
MT Newswires Live
Nov 06, 2024
Praxis Precision Medicines (PRAX) reported a Q3 net loss Wednesday of $2.75 per diluted share, compared with a loss of $2.72 a year earlier.
Analysts polled by Capital IQ expected a loss of $1.95.
Collaboration revenue for the quarter ended Sept. 30 was $302,000, down from $468,000 a year earlier.
Analysts surveyed by Capital IQ expected $300,000.
As of Sept. 30, the company said it had $411.2 million in cash, cash equivalents and marketable securities.
The company's shares were down 6.8% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.